References
- Smith TW. Digitalis: mechanisms of action and clinical use. N Engl J Med 1988: 318(6): 358–65
- Smith TW, Braunwald E, Kelly RA. The management of heart failure. In: Braunwald E, ed. Heart disease: a textbook of cardiovascular medicine. 4th ed. Philadelphia: Saunders, 1992: 507
- Suki WN. Renal hemodynamic consequences of angiotensin-converting enzyme inhibition in congestive heart failure. Arch Intern Med 1989; 149(3): 669–73
- Dzau VJ, Colucci WS, Williams GH, et al. Sustained effectiveness of converting-enzyme inhibition in patients with severe congestive heart failure. N Engl J Med 1980; 302(25): 1373–9
- The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987: 316(23): 1429–35
- Gottlieb SS, Web MR. Renal effects of angiotensin-converting enzyme inhibition in congestive heart failure. Am J Cardiol 1990; 66(11): 14–20D, discussion 20–1D
- Gottlieb SS, Robinson S, Weir MR, et al. Determinants of the renal response to ACE inhibition in patients with congestive heart failure. Am Heart J 1992; 124(1): 131–6
- Packer M, Lee WH, Medina N, et al. Functional renal insufficiency during long-term therapy with Captopril and enalapril in severe chronic heart failure. Ann Intern Med 1987; 106(3): 346–54
- Ichikawa I, Pfeffer JM, Pfeffer MA, et al. Role of angiotensin II in the altered renal function of congestive heart failure. Circ Res 1984; 55(5): 669–75
- Textor SC, Bravo EL, Fouad FM, et al. Hyperkalemia in azotemic patients during angiotensin-converting enzyme inhibition and aldosterone reduction with Captopril. Am J Med 1982; 73(5): 719–25
- Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med 1986; 314(24): 1547–52
- Lass NA, dock D, Goldberg LI. Cardiovascular and renal hemodynamic effects of intravenous infusions of the selective DA1 agonist, fenoldopam, used alone or in combination with dopamine and dobutamine. Circulation 1988; 78(5 Pt 1): 1310–5
- Dzau VJ, Packer M, Lilly LS, et al. Prostaglandins in severe congestive heart failure: relation to activation of the renin-angiotensin system and hyponatremia. N Engl J Med 1984; 310(6): 347–52